Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ADHD combo drug trial stops early – only 2 teens enrolled

NCT ID NCT06673368

Symptom relief Sponsor: Neurocentria, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of two drugs, NRCT-101SR and NRCT-202XR, for teens with ADHD. The goal was to see if the combo could ease symptoms and reduce side effects better than one drug alone. However, the study was terminated early and only enrolled 2 participants, so no meaningful results were obtained.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NRCT-101SR and NRCT-202XR (drug combination)
What this could lead to
If it had succeeded, this could have pointed toward a new combination treatment for ADHD that reduces side effects.
What could go wrong
The trial was terminated early with only 2 participants, so no conclusions can be drawn. It is very early-stage and uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

2 people

The number who actually took part.

Started

Feb 2025

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Male or female, 13-17 years of age at screening. 2. Has a prior primary diagnosis of ADHD according to the DSM-5 classification evident by a medical record and confirmed with MINI using DSM-5 probes. 3. Is taking ADHD medication 4-7 days/week, for at least 4 weeks at Screening and at least 6 weeks at Baseline. 4. Has side effects identified using SDSE-RS at Screening and Baseline. 5. CGI-S ≥ X (blinded) at Screening and Baseline. 6. Must be fluent in English and communicate effectively with others. 7. Both subject and parent/guardian willing and able to give informed assent/consent. 8. Parent/guardian willing to serve as informant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD

Contacts and locations

Locations

  • Accel Research Site-Maitland Clinical Research Unit

    Maitland, Florida, 32751, United States

  • Boston Clinical Trials LLC

    Boston, Massachusetts, 02131, United States

  • CenExel iRS - iResearch Savannah

    Savannah, Georgia, 31405, United States

  • Center For Psychiatry and Behavioral Medicine

    Las Vegas, Nevada, 89128, United States

  • iResearch Atlanta

    Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.